The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid structural shifts in the global healthcare sector, Amgen has emerged as a leader in the biosimilars segment to offset competitive pressures on its innovative branded drugs. New product launches, including Wezlana, Bekemv, and Pavblu, are driving sales and mitigating the impact of patent expirations on legacy products. According to reports, the company is leveraging this strategic pivot to sustain revenue growth as its legacy branded portfolio faces significant patent cliffs.
This strategic move comes at a critical time for the pharmaceutical industry, as major peers like Pfizer and Novartis face similar challenges regarding patent expirations. In comparison to peer performance, while Pfizer's recent earnings showed growth in its oncology segment, Amgen is aggressively targeting market share from global blockbusters like Opdivo and Keytruda through its biosimilar pipeline. Per market data, the success of these biosimilars is essential for maintaining profit margins relative to competitors who rely more heavily on de novo drug discovery.
Sign in to access this content
Sign InRegarding market performance, AMGN stock stood at $337.60 (close June 18, 2026), having reached a session high of $345.00. Investors are now looking toward upcoming U.S. economic catalysts, such as Retail Sales data, to gauge consumer spending strength and its broader impact on the healthcare sector. Technical support levels remain near the recent low of $334.05, which serves as a key monitoring point for short-term traders.